Amneal Exceeds 2025 Guidance and Eyes More Growth for 2026 as Portfolio Strengthens
Strong 2025 Performance Across All Metrics Sets Up Positive Outlook
Amneal Pharmaceuticals (NASDAQ: AMRX) wrapped up 2025 by delivering on, and in some cases outperforming, its full-year guidance—demonstrating the durability of its business model and clarity of execution. According to the company's just-released results, 2025 net revenue reached $3.02 billion, growing 8% year-over-year, while GAAP net income swung from a $117 million loss in 2024 to a $72 million profit in 2025. Adjusted EBITDA climbed to $688 million, up 10% year-over-year, and adjusted diluted EPS jumped 43% to $0.83. Management expects this momentum to carry into 2026, guiding for $3.05–$3.15 billion in revenue, $720–$760 million in adjusted EBITDA, and $0.93–$1.03 in adjusted diluted EPS—all pointing to further profit and cash flow growth.
Segment Growth and Margin Expansion Highlight Diversification Benefits
Amneal’s three main business segments—Specialty, Affordable Medicines, and AvKARE—all contributed to top-line gains. Specialty net revenue rose 19% for the year, Affordable Medicines increased 4%, and AvKARE grew 12%. Notably, gross margin improvements were seen across the board, especially in the Specialty segment, where non-GAAP gross margin for Q4 hit 75.7%, well above Affordable Medicines and AvKARE. Growth was supported by new launches (including the CREXONT® neurology product and the BREKIYA® autoinjector), additional biosimilar approvals, and robust government channel sales for AvKARE.
| Segment | 2025 Net Revenue ($M) | 2024 Net Revenue ($M) | YOY Growth (%) | 2025 Gross Margin (%)* |
|---|---|---|---|---|
| Specialty | 528.51 | 445.75 | 18.6 | 79.3 |
| Affordable Medicines | 1,745.52 | 1,685.26 | 3.6 | 41.8 |
| AvKARE | 744.73 | 662.95 | 12.3 | 19.7 |
*Non-GAAP, full year 2025
Cash Flow Improves, Leverage Decreases Following Debt Refinancing
Operational efficiency provided further upside—operating cash flow for 2025 hit $340 million, higher than the previous year, and capital expenditures clocked in at $89 million. Notably, Amneal completed a major debt refinancing with a new seven-year term loan and $600 million in senior notes, helping maintain ample liquidity (over $282 million in cash at year-end) and drop net leverage to 3.5x from 3.9x a year earlier. Management expects further leverage reduction in 2026.
| Metric | 2025 | 2024 |
|---|---|---|
| Operating Cash Flow ($M) | 340.00 | 295.10 |
| Net Leverage (x) | 3.5 | 3.9 |
| Cash & Equivalents ($M, End of Year) | 282.03 | 110.55 |
2026 Guidance Signals Confidence in Continued Expansion
Looking ahead, Amneal projects Affordable Medicines will lead 2026’s organic growth (+7–8% revenue expected), while the Specialty segment is expected to hold steady after last year’s launch-driven surge. AvKARE is forecast to generate $625–$700 million in net revenue. Management also anticipates adjusted EBITDA of $720–$760 million, $325–$375 million in operating cash flow, and up to $110 million in capital expenditures as investments in new products and operating capacities continue. Adjusted diluted EPS is expected to hit $0.93–$1.03, extending the company’s path to higher shareholder value.
| 2026 Guidance | 2025 Actuals |
|---|---|
| Net Revenue: $3.05–$3.15B | $3.02B |
| Adjusted EBITDA: $720–$760M | $688M |
| Adjusted Diluted EPS: $0.93–$1.03 | $0.83 |
| Operating Cash Flow: $325–$375M | $340M |
| Capital Expenditures: ~$110M | $89M |
Takeaway: Amneal’s Execution and Balance Sheet Leave Room for Upside
After six straight years of steady growth, Amneal’s latest results reinforce management’s claims of a resilient, diversified strategy and a disciplined operational focus. With new product launches, improving margins, and prudent financial management, the company appears well-positioned for continued outperformance. As always, investors should monitor execution and regulatory developments, but Amneal’s track record and 2026 outlook offer a data-driven case for optimism in the generic and specialty pharma space.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI